MEI Pharma, Inc. Stock Deutsche Boerse AG
Equities
MMI0
US55279B3015
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 EUR | -17.32% | -.--% | -.--% |
Sales 2024 * | 65.3M 60.15M | Sales 2025 * | 6.25M 5.76M | Capitalization | 21.25M 19.58M |
---|---|---|---|---|---|
Net income 2024 * | 26M 23.95M | Net income 2025 * | -40M -36.85M | EV / Sales 2024 * | 0.33 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.4 x |
P/E ratio 2024 * |
0.88
x | P/E ratio 2025 * |
-0.56
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.34% |
Latest transcript on MEI Pharma, Inc.
1 day | -17.32% |
Managers | Title | Age | Since |
---|---|---|---|
David Urso
CEO | Chief Executive Officer | 60 | 14-03-06 |
Justin File
DFI | Director of Finance/CFO | 53 | 23-06-11 |
Caroline Ruiz
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 18-02-25 |
Thomas Reynolds
BRD | Director/Board Member | 65 | 13-02-10 |
Charles Baltic
CHM | Chairman | 63 | 11-10-19 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.34% | 62.59B | |
-3.05% | 41.18B | |
+44.76% | 40.29B | |
-8.29% | 27.9B | |
+12.55% | 26.21B | |
-21.60% | 19.09B | |
+5.70% | 13.08B | |
+24.54% | 12.26B | |
+27.52% | 12.05B |
- Stock Market
- Equities
- MEIP Stock
- MMI0 Stock